Findings {#Sec1}
========

Background {#Sec2}
----------

Esophageal cancer (EC) is the seventh most common cancer worldwide and the sixth most common cause of cancer death \[[@CR1]\]. There are two main types of esophageal cancer -- adenocarcinoma and squamous cell carcinoma with distinct etiology and epidemiology.

Esophageal adenocarcinoma (EAC) is one of the fastest rising cancers in Western society. Incidence has increased by 600% within the last 30 years \[[@CR2]\]. The reason of increasing incidence is not entirely clear but the main risk factors are male sex (5 more often than female sex), Caucasian race, chronic reflux disease and visceral obesity \[[@CR2]\]. In contrast, esophageal squamous cell carcinoma (ESCC) is more prevalent in the developing world with very high incidence areas found in East Asia mainly in China \[[@CR3]\]. While the main risk factors are smoking and alcohol consumption, high diets in N-nitroso compounds, fungal toxins, low in selenium, zinc, vitamins A and C and highly salted meats are also discussed as potential risk factors.

Both EAC and ESCC are usually detected at an advanced stage, requiring a multimodal concept of therapy, however the overall survival of esophageal cancer remains lower than other solid tumors \[[@CR4]\]. Although the treatments have made great progress, the prognosis for patients with advanced disease still remains poor and unsatisfactory \[[@CR5]\]. Potentially curative treatments are followed by high rates of disease recurrence. All these facts together clearly indicate the need for a molecular biomarker for esophageal cancer enabling earlier detection and prognostic stratification.

MicroRNA (miRNA) are short non-coding RNA with ability to regulate important cellular processes as differentiation, cell cycle, proliferation or apoptosis. They are known to be deregulated in most tumor types \[[@CR6]\], in which they can act as tumor suppressors or oncogenes. Altered miRNA expression profiles are intensively studied also in esophageal cancer. In this study, we hypothesized that selected miRNAs can be identified as diagnostic and/or prognostic biomarkers in EC. Thus, we analyzed 9 candidate miRNAs in EAC, ESCC and non-tumor esophageal mucosa and investigated their potential for diagnostic and prognostic usage in EC.

Methods {#Sec3}
-------

### Study population {#Sec4}

A total of 62 tissue samples from two esophageal cancer cohorts were included in the study. First cohort (Motol University Hospital, 3rd Department of Surgery, Prague, Czech Republic) consisted of 17 EAC and 5 ESCC cases, whereas for 17 EAC cases paired esophageal mucosa samples were available. Second cohort (Palacky University, Medical Faculty, Olomouc, Czech Republic) consisted of 6 EAC and 17 ESCC cases. All subjects were of the same ethnicity (Caucasian). Clinico-pathological features including age, sex, histology and treatment were recorded and summarized in Table [1](#Tab1){ref-type="table"}. Written informed consent was obtained from the patients before starting this study. The study has been approved by the local ethical committees (Prague, Olomouc). Table 1**Patient characteristicsCharacteristicPrague cohortOlomouc cohortTotal2223Gender**Male**2018**Female**25Age59 (49--70)58 (34--79)Histology**Adenocarcinoma**176**Squamous cell carcinoma**517Pre-operative chemotherapy**Adenocarcinoma**CDDP+FU 2x06ECF/ECX170**Squamous Cell carcinoma**CDDP+FU 2x317ECF/ECX2** **0Tumor location**Upper esophagus**00**Middle esophagus**2011**Lower esophagus**212**

### Tissue sample preparation and miRNA isolation {#Sec5}

Forty-five samples of tumor tissue and seventeen samples of non-cancerous esophageal mucosa were collected and stored in RNAlater (Ambion, USA). Afterward, tissue samples were homogenized (MagnaLyser, Roche), and total RNA enriched for small RNA fraction was isolated using fenol-chloroform extraction with TRIzol reagent (Ambion, USA). Concentration and purity of RNA were determined using a Nanodrop ND-1000 (Thermo Scientific, USA), and RNA integrity was measured by Agilent 2100 Bioanalyzer using Agilent RNA 6000 Nano Kit (Agilent Technologies, USA). Samples were either stored at -80°C or further processed.

### Quantitative real-time PCR {#Sec6}

cDNA was synthesized from total RNA using miRNA-specific primers according to the Taq-Man MicroRNA Assay protocol (Applied Biosystems, USA). Real-time polymerase chain reaction (PCR) was performed according to manufacturing protocol (MicroRNA Assay, Applied Biosystems, USA) using the Applied Biosystems 7500 Instrument as described previously \[[@CR7]\]. All reactions were run in triplicate, and average threshold cycle and SD values were calculated.

### Data normalization and statistical analysis {#Sec7}

The threshold cycle data were calculated by SDS 2.0.1 software (Applied Biosystems, USA). The average expression levels of measured miRNAs were normalized using RNU44 as reference gene and subsequently analyzed by the 2^-ΔCt^ method. Differences between expression levels in paired samples were evaluated by non-parametric Wilcoxon test. Differences between miRNA levels in EAC and ESCC samples were evaluated by non-parametric Mann--Whitney *U*-test. Survival analyses were carried out using the log-rank test and Kaplan-Meier survival analysis. All calculations were performed using Prism version 6.00 (GraphPad Software, San Diego, CA, USA). P-values of less than 0.05 were considered statistically significant.

Results {#Sec9}
-------

### miR-203 and miR-21 are able to distinguish EAC and normal tissue {#Sec8}

To determine whether the selected miRNAs (miR-200c, miR-25, miR-27a, miR-7a, miR-29c, miR-203, miR-148a, miR-21 a miR-31) have a diagnostic potential, expression levels were analyzed for each miRNA in 17 EAC samples and 17 paired adjacent mucosa. There were 2 miRNAs differentially expressed in tumor tissue and adjacent mucosa. MiR-203 levels were significantly down-regulated in tumor tissue (fold change 0,19; p \< 0,0001), miR-21 levels were significantly up-regulated in tumor tissue (fold change 40,38; p = 0,0004) (Figure [1](#Fig1){ref-type="fig"} A,B). No significant difference was observed in the other examined miRNA as summarized in Table [2](#Tab2){ref-type="table"}.Figure 1Normalized expression levels of miR-203 and miR-21 in esophageal adenocarcinoma tissue and control mucosa. **A)** MiR-203 is decreased in esophageal adenocarcinoma compared to paired adjacent mucosa (P \< 0.0001). **B)** MiR-21 is increased in esophageal adenocarcinoma compared to paired adjacent mucosa (P = 0.0004). **C)** MiR-148a is up-regulated in esophageal adenocarcinoma compared to esophageal squamous cell carcinoma (P = 0.0014). **D)** MiR-29c is up-regulated in esophageal adenocarcinoma compared to esophageal squamous cell carcinoma (P = 0.0446). EAC -- esophageal adenocarcinoma; ESCC -- esophagus squamous cell carcinoma; \*P \< 0.05; \*\*P \< 0.001; \*\*\*P \< 0.0001Table 2**MiRNA expression levels in adenocarcinoma and paired non-tumoral esophageal mucosaAdenocarcinoma (n = 17)Mucosa (n = 17)FCp-valueMedianMedian(25%--75% percentile)(25%--75% percentile)miR-203**2,31212,280,19**\< 0,0001**(0,5304--5,990)(9,139--19,73)**miR-21**2,4630,0606440,38**0,0004**(0,8149--9,648)(0,06729--0,9838)miR-250,075570,079590,950,6221(0,02829--0,3545)(0,02275--0,2205)miR-27a1,7632,740,640,1006(1,236--3,482)(2,096--5,082)miR-310,67390,46591,450,1201(0,3100--2,596)(0,4084--0,8982)miR-200c1,7181,8840,920,2036(1,182--2,705)(1,496--4,017)let-7a0,150,1960,770,3394(0,1143--0,4092)(0,04641--0,2439)miR-29c0,033890,16470,210,9697(0,01787--0,7736)(0,0233--0,6866)miR-1480,17790,17851,000,1893(0,1244--0,3107)(0,1050--0,5636)MiRNAs with significant differences are bolded.

### miR-148 and miR-29c have ability to distinguish EAC and ESCC tissues {#Sec10}

To determine whether different expression levels of analyzed miRNAs exist in EAC and ESCC tissues, we performed qPCR analysis of selected miRNAs (miR-200c, miR-25, miR-27a, miR-7a, miR-29c, miR-203, miR-148a, miR-21 a miR-31) in 22 ESCC samples and 22 EAC samples. We found that miR-148 and miR-29c were decreased in ESCC when compared to EAC and have ability to significantly distinguish ESCC and EAC tissues (fold change 0,32; p = 0,0014; fold change 0,62; p = 0,0446), respectively (Figure [1](#Fig1){ref-type="fig"}C,D). No significant difference was observed in the other examined miRNA as summarized in Table [3](#Tab3){ref-type="table"}.Table 3**Comparison of miRNAs expression levels in ESCC and EAC tissuesEsophageal squamous cell carcinoma (n = 22)Adenocarcinoma (n = 22)FCp-valueMedianMedian(25%--75% percentile)(25%--75% percentile)miR-148**0,10310,32130,32**0,0014**(0,04630--0,2080)(0,1358--0,8261)**miR-29c**0,027250,044020,62**0,0446**(0,006621--0,04527)(0,02413--0,5075)miR-210,86190,90010,960,2093(0,3963--2,328)(0,6343--6,177)miR-250,2220,14951,480,9266(0,009942--0,5544)(0,03441--0,4671)miR-27a3,8021,5922,390,1333(1,563--7,393)(1,168--3,997)miR-310,80680,55171,460,8971(0,3731--1,394)(0,31--2,596)miR-200c1,6812,1550,780,6304(0,8033--3,385)(1,201--3,419)let-7a0,47390,15882,980,1168(0,1811--0,9559)(0,1177--0,3838)miR-2033,9762,11,890,6304(0,3679--14,51)(0,1074--5,347)MiRNAs with significant differences are bolded.

### MiR-148 and miR-203 are associated with prognosis in EC patients {#Sec11}

EAC patients with decreased miR-203 levels showed significantly shorter disease free survival (p = 0,026). Down-regulation of miR-148 was associated with significantly shorter overall survival (p = 0,0014) in ESCC patients. Interestingly, opposite observation was reached in EAC patients, where cases with up-regulation of miR-148 showed significantly shorter disease free survival (p = 0,0145) and overall survival (p = 0,0016), indicating opposite functioning of miR-148 in EAC and ESCC (Figure [2](#Fig2){ref-type="fig"}A-D). There was no association with survival observed in other examined miRNAs.Figure 2Survival analysis of miR-203 and miR-148 tissue levels in esophageal squamous cell carcinoma and esophageal adenocarcinoma patients. **A)** Esophageal adenocarcinoma patients with low level of miR-203 have shorter disease free survival (P = 0.026). **B)** Esophageal adenocarcinoma patients with high level of miR-148 have shorter disease free survival (P = 0.0145). **C)** Esophageal adenocarcinoma patients with high level of miR-148 have shorter overall survival (P = 0.0016). **D)** Esophageal squamous cell carcinoma patients with low level of miR-148 have shorter overall survival (P = 0.0014). DFS -- disease free survival; OS -- overall survival.

Discussion {#Sec12}
----------

Our results indicate that miR-203 plays role of tumor suppressor in EAC since the expression levels of this miRNA were significantly decreased in tumor tissue of EAC patients. Those results are in compliance with another studies, where miR-203 displayed stepwise decrease in expression during malignant progression from healthy tissue through Barrett's esophagus to EAC \[[@CR8]-[@CR11]\]. Moreover, survival analysis showed significantly shorter disease free survival of the EAC patients with low expression of miR-203 in our study. Another miRNA observed to have different expression in EAC tissue and adjacent mucosa is miR-21, which is well known as oncogene. In our study, expression levels of miR-21 were significantly higher in EAC tissue, which is in concordance with the several previous studies \[[@CR8],[@CR10]-[@CR12]\]. We have not found association of miR-21 and survival in our study, which is contradictory to meta-analysis performed by Fu *et al.*, where up-regulation of miR-21 could predict unfavorable prognosis in esophageal cancer \[[@CR12]\].

The second aim of our study was to discriminate EAC from ESCC tissue. For the first time, we found that the expression levels of miR-148a and miR-29c are significantly higher in EAC when compared to ESCC tissue. Moreover up-regulation of miR-148 could predict unfavorable prognosis in EAC cancer and surprisingly favorable prognosis in ESCC patients. It seems that miR-148 can play the role of tumor suppressor or tumor oncogene depending on histological subtype of esophageal cancer.

MiR-148 was not yet studied in association with esophageal cancer, but it is known to act as oncogene and also as tumor suppressor in different tumor types. Thus, Kim *et al.* has reported the definition of miR-148a as a novel prognostic oncomiR in glioblastoma with high levels considered as a risk factor for glioblastoma patients survival \[[@CR13]\]. When analyzed in vitro, miR-148a overexpression increased cell growth, survival, migration, and invasion in glioblastoma cells \[[@CR13]\]. On the other hand, in gastric cancer (GC), miR-148 acts as tumor suppressor and its down-regulation is linked to the poor prognosis. MiR-148a levels were found to be decreased in GC cell lines and in GC tissue samples when compared to the adjacent normal gastric tissues and in different clinical stages of GC \[[@CR14]-[@CR18]\]. Low expression of miR-148a was significantly correlated with an advanced clinical stages, lymph node metastasis, and poor clinical outcome \[[@CR14]\].

Our data indicate, that miR-203 and miR-21 could serve as diagnostic biomarkers. Further, miR-29c and miR-148 have ability to distinguish between EAC and ESCC histological subtypes of esophageal cancer. In future, the diagnosis could be assessed for instance from non-invasive brush biopsy of esophagus \[[@CR19]\]. Moreover miR-203 and miR-148 could serve as prognostic biomarker in EAC, and miR-148 also in ESCC patients. Further studies are needed to evaluate mechanistically dual functioning of miR-148 in EAC and ESCC carcinogenesis.
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